UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private
Issuer
Pursuant to Rule 13a-16 or
15d-16
under the Securities Exchange Act of 1934
For the month of September 2026
Commission file number: 001-42375
Polyrizon Ltd.
(Translation of registrant’s name into English)
8 Ha-Pnina Street
Raanana, 4321545, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
CONTENTS
Attached hereto and incorporated herein is the
Registrant’s press release issued on September 4, 2026, titled “Polyrizon Ltd. Announces Closing of $4.0 Million Registered
Direct Offering and Private Placement.”
The first paragraph of the press release attached to this Report of
Foreign Private Issuer on Form 6-K as Exhibit 99.1 is incorporated by reference into the Registrant’s Registration Statements on Form
S-8 (File No. 333-284410 and 333-288923)
and Form F-3 (333-291368),
filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent
not superseded by documents or reports subsequently filed or furnished.
EXHIBIT INDEX
| Exhibit No. |
|
|
| 99.1 |
|
Press release titled: “Polyrizon Ltd. Announces Closing of $4.0 Million Registered Direct Offering and Private Placement” |
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
Polyrizon Ltd. |
| |
|
| Date: September 4, 2026 |
By: |
/s/ Tomer Izraeli |
| |
Name: |
Tomer Izraeli |
| |
Title: |
Chief Executive Officer |
Exhibit 99.1
Polyrizon Ltd. Announces Closing of $4.0 Million
Registered Direct Offering and Private Placement
RAANANA, ISRAEL, Sept. 04, 2026 (GLOBE NEWSWIRE)
-- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a development-stage biotech company specializing in the development
of innovative intranasal hydrogels, today announced the closing of its previously announced registered direct offering and concurrent
private placement. The Company issued to a single institutional investor Ordinary Shares and pre-funded warrants in a registered direct
offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate
gross proceeds to the Company from both transactions were approximately $4.0 million.
The transactions consisted of the sale of 333,333
Units (or Pre-Funded Units), each consisting of one (1) Ordinary Share (or one (1) Pre-Funded Warrant to purchase one (1) Ordinary Share)
and one (1) Common Warrant to purchase one (1) Ordinary Share, at a combined offering price of $12.00 per Unit (or $11.99999 per Pre-Funded
Unit, equal to the offering price per Unit minus an exercise price of $0.00001 per Pre-Funded Warrant). In the registered direct offering,
the Company issued 232,500 Ordinary Shares and 30,000 Pre-Funded Warrants. In the concurrent private placement, the Company issued 70,833
PIPE Pre-Funded Warrants and 333,333 PIPE Common Warrants. The Pre-Funded Warrants are immediately exercisable (subject to registration
for unregistered PIPE Pre-Funded Warrants) and may be exercised at any time until exercised in full. The Common Warrants have an exercise
price of $12.00 per share.
The transactions closed on September 4, 2026.
The Company expects to use the net proceeds from the offerings, together with its existing cash, for general corporate purposes and working
capital.
Aegis Capital Corp. acted as exclusive placement
agent for the offerings. Meitar | Law Offices acted Israeli counsel to the Company. Kaufman & Canoles, P.C. acted counsel to Aegis
Capital Corp.
The registered direct offering was made pursuant
to an effective shelf registration statement on Form F-3 (No. 333-291368) previously filed with the U.S. Securities and Exchange Commission
(SEC) and declared effective by the SEC on December 3, 2025. A final prospectus supplement and accompanying prospectus describing the
terms of the proposed offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov.
Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained, when available, by contacting Aegis
Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com,
or by telephone at +1 (212) 813-1010.
The offer and sale of the securities in the private
placement were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as
amended (the “Securities Act”), or applicable state securities laws. Accordingly, the securities may not be reoffered or resold
in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements
of the Securities Act and such applicable state securities laws. The securities were offered only to accredited investors. Pursuant to
a registration rights agreement with the investors, the Company has agreed to file one or more registration statements with the SEC covering
the resale of the Ordinary Shares and the Shares issuable upon exercise of the pre-funded warrants and warrants.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Polyrizon Ltd.
Polyrizon is a development stage biotech company
specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based
shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial
tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring
building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield
containment barrier in the nasal cavity. Polyrizon is further developing certain aspects of its C&C hydrogel technology such as the
bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional
technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients,
or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as
“expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example,
the Company is using forward-looking statements when it discusses the intended use of proceeds from the offering. Forward-looking statements
are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance
that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is
expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could
cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description
of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the
Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual
report filed with the SEC on March 25, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date
the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent
events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent
required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn
that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and
links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference
into this press release. Polyrizon is not responsible for the contents of third-party websites.
Michal Efraty
Investor Relations
IR@polyrizon-biotech.com